Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
Int J Obes (Lond). 2022 Jul;46(7):1366-1374. doi: 10.1038/s41366-022-01122-2. Epub 2022 Apr 26.
BACKGROUND/OBJECTIVES: The association between vitamin D and DSPN has been investigated in cross-sectional studies in individuals with diabetes. However, evidence from prospective and population-based studies is still lacking. Also, the potential modifying effect of obesity and glucose tolerance has not been investigated. Therefore, we examined the cross-sectional and prospective associations of serum 25(OH)D with DSPN and assessed possible effect modifications.
SUBJECTS/METHODS: The study included individuals aged 62-81 years who participated in the German KORA F4 (2006-2008) and FF4 (2013-2014) studies. DSPN was assessed using the Michigan Neuropathy Screening Instrument. Cross-sectional analyses (n = 1065; 33% of the participants had obesity) assessed the associations of baseline 25(OH)D with prevalent DSPN, while prospective analyses (n = 422) assessed the associations of 25(OH)D with incident DSPN.
No association was found between 25(OH)D and prevalent DSPN in the total sample after adjustment for age, sex, season of blood sampling, BMI, metabolic variables, lifestyle factors, and comorbidities. However, a decrease by 10 nmol/L in 25(OH)D was associated with prevalent DSPN (RR (95% CI) 1.08 (1.01, 1.16)) in individuals with obesity but not in normal-weight individuals (RR (95% CI) 0.97 (0.92, 1.02), p = 0.002). No evidence for effect modification by glucose tolerance was found (p > 0.05). In the prospective analysis, 25(OH)D levels in the first and second tertiles were associated with higher risk of DSPN (RR (95% CI) 1.18 (1.02; 1.38) and 1.40 (1.04; 1.90)) compared to the third tertile after adjustment for age, sex, season of blood sampling, and BMI. There was no evidence for effect modification by obesity or glucose tolerance categories.
Our study did not show consistent evidence for cross-sectional and prospective associations between serum 25(OH)D levels and DSPN in the total study population of older individuals. However, there was evidence for an association between lower serum 25(OH)D levels and higher prevalence of DSPN in individuals with obesity.
背景/目的:已有横断面研究调查了维生素 D 与糖尿病周围神经病变(DSPN)之间的关联。然而,仍缺乏前瞻性和基于人群的研究证据。此外,肥胖和葡萄糖耐量的潜在调节作用尚未得到研究。因此,我们检测了血清 25(OH)D 与 DSPN 的横断面和前瞻性关联,并评估了可能的修饰效应。
受试者/方法:该研究纳入了年龄在 62-81 岁之间的参加德国 KORA F4(2006-2008 年)和 FF4(2013-2014 年)研究的个体。使用密歇根神经病变筛查工具评估 DSPN。横断面分析(n=1065;参与者中有 33%为肥胖)评估了基线 25(OH)D 与现患 DSPN 的关联,而前瞻性分析(n=422)评估了 25(OH)D 与新发 DSPN 的关联。
在调整年龄、性别、采血季节、BMI、代谢变量、生活方式因素和合并症后,总样本中 25(OH)D 与现患 DSPN 之间未发现关联。然而,与正常体重者相比,25(OH)D 每降低 10nmol/L,肥胖者现患 DSPN 的风险增加(RR(95%CI)1.08(1.01,1.16))(RR(95%CI)0.97(0.92,1.02),p=0.002)。未发现葡萄糖耐量的修饰作用(p>0.05)。在前瞻性分析中,与第三三分位相比,第一和第二三分位的 25(OH)D 水平与 DSPN 的风险较高相关(RR(95%CI)1.18(1.02;1.38)和 1.40(1.04;1.90)),校正年龄、性别、采血季节和 BMI 后。肥胖或葡萄糖耐量类别的修饰作用无证据。
我们的研究在年龄较大的个体的总研究人群中没有一致的证据表明血清 25(OH)D 水平与 DSPN 之间存在横断面和前瞻性关联。然而,有证据表明,血清 25(OH)D 水平较低与肥胖个体中 DSPN 的患病率较高有关。